Docetaxel (Taxotere) in the treatment of non-small cell lung cancer: an international update. Academic Article uri icon

Overview

abstract

  • Based on the results of two recent trials, docetaxel (Taxotere; Aventis, Antony, France) is now the drug of choice for the treatment of advanced non-small cell lung cancer that is refractory to primary chemotherapy. Trials are testing the role of docetaxel in the induction setting, as well as concomitantly with radiation therapy.

publication date

  • February 1, 2001

Research

keywords

  • Antineoplastic Agents, Phytogenic
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms
  • Paclitaxel
  • Radiation-Sensitizing Agents
  • Taxoids

Identity

Scopus Document Identifier

  • 0035087566

PubMed ID

  • 11284618

Additional Document Info

volume

  • 28

issue

  • 1 Suppl 2